Document Type
Article
Publication Date
11-12-2026
Abstract
Background
Computed tomography (CT) stages pancreatic ductal adenocarcinoma (PDAC) but does not read out the treatment-guiding tumour biology, requiring biopsy. Whether an imaging-biology relationship discovered in preclinical MRI holds independently in human CT is unknown.Methods
One pipeline was applied to two PDAC cohorts: longitudinal 9.4 T multi-parametric MRI (169 sessions; 1002 image series, 471 quantitative maps) with terminal histopathology in male C57BL/6 mice bearing orthotopic KPC-derived tumours treated with gemcitabine, a dendritic-cell vaccine, both, or neither, and abdominal CT with matched proteogenomics from CPTAC-PDA. Radiomics and frozen foundation-model embeddings were modelled under grouped cross-validation against five pre-specified paired endpoints, with no cross-species transfer of features, weights, or labels.Findings
Applied independently, the pipeline recovered four matched molecular endpoints in both species (CD8 infiltration, stromal collagen, CD8:CD68 immune balance, cytolytic activity), with areas under the receiver-operating-characteristic curve (AUROCs) of 0.938–0.960 in mice and 0.780–0.856 in humans. Survival concordance indices were 0.729 and 0.689. After adjustment for age, stage, and grade, the human imaging score remained independently prognostic (hazard ratio 1.87 per SD, 95% CI 1.32 to 2.66; p < 0.001 [Wald test]; combined concordance index 0.726 versus 0.611 for clinical covariates). Findings held in portal-venous-restricted analysis; frozen embeddings outperformed end-to-end fine-tuning in both arms.Interpretation
One pipeline recovered matched PDAC biology in mouse MRI and human CT, supporting preclinical imaging to nominate non-invasive CT biomarker candidates for biopsy-sparing PDAC trial stratification, pending prospective external validation.Recommended Citation
Yu G, Zhang Z, Eresen A, et al. Foundation-model imaging biomarkers for pancreatic cancer: cross-species discovery of conserved tumour biology in mouse MRI and human CT. eBioMedicine. 2026;134: 106545. https://doi.org/10.1016/j.ebiom.2026.106545
Supplementary Methods, Figs. S1–S6, and Tables S1–S15.
Copyright
The authors
Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Included in
Animal Experimentation and Research Commons, Cancer Biology Commons, Medicinal and Pharmaceutical Chemistry Commons, Oncology Commons, Other Pharmacy and Pharmaceutical Sciences Commons
Comments
This article was originally published in eBioMedicine, volume 134, in 2026. https://doi.org/10.1016/j.ebiom.2026.106545